Citius Oncology, Inc.: Form 10-Q for the period ended Dec 31, 2024
Filed with the SEC on Feb 14, 2025 and accepted by EDGAR at Feb 14, 2025, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-10-01 to 2024-12-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Income tax | 3 months2024-10-01 to 2024-12-31 | $264.2k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-10-01 to 2024-12-31 | −$6.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-10-01 to 2024-12-31 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-10-01 to 2024-12-31 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-10-01 to 2024-12-31 | 71,552,402 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Cash and equivalents | At period end2024-12-31 | $112 | us-gaap:Cash |
| Current assets | At period end2024-12-31 | $17.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $90.5m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $43.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $49.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $41.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-25-014320. Last ingested by Listed: Nov 4, 2026, 17:46 ET. Listed shows no prices and gives no investment advice.